Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2022 · 10-Q
Revenue$13.98M$13.98M+2.6% vs Q2 2021 Net Income-$3.88M-$3.88MN/M vs Q2 2021 EPS Diluted-$0.21-$0.21N/M vs Q2 2021 Gross Profit$8,989,949+11.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$308,128+62.3% Free Cash Flowderived$281,273+69.3% Margins · derivedGross margin64.3%+5.3 pt vs Q2 2021
Operating margin-28.0%−30.5 pt vs Q2 2021
Net margin-27.8%−30.4 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end